State Street’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

State Street’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-371,156	Closed	-$1.5M	–	4453
2023 Q4	$1.5M	Buy	371,156 +2,496	+0.7%	+$7.62K	﹤0.01%	3389
2023 Q3	$992K	Buy	368,660 +1,144	+0.3%	+$4.48K	﹤0.01%	3529
2023 Q2	$3.43M	Buy	367,516 +70,652	+24%	+$696K	﹤0.01%	3177
2023 Q1	$2.64M	Buy	296,864 +25,383	+9%	+$249K	﹤0.01%	3247
2022 Q4	$1.35M	Buy	271,481 +23,200	+9%	+$136K	﹤0.01%	3489
2022 Q3	$1.44M	Buy	248,281 +14,388	+6%	+$102K	﹤0.01%	3500
2022 Q2	$1.29M	Buy	233,893 +51,232	+28%	+$423K	﹤0.01%	3586
2022 Q1	$2.11M	Buy	182,661 +55,865	+44%	+$597K	﹤0.01%	3546
2021 Q4	$1.61M	Buy	+126,796	New	+$1.91M	﹤0.01%	3701

State Street's THRX Position: Q1 2024 in Review

State Street sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 371,156 shares — an estimated $1.5M sold.

State Street first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $3.43M in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

State Street reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
State Street sold 371,156 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $1.5M.
State Street first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
State Street's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $3.43M in Q2 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on State Street's 13F filing for Q1 2024, filed 15 May 2024.